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Supplement
but may entail repeated rectal examinations,
prostate-specific antigen estimations and
repeat prostate biopsies;
• Radical prostatectomy (RP), which
involves co plete surgical removal of the
prostate gland, seminal vesicles, ampulla of








Objective:  To assess the psychological impact of the different treatments for localised 
prostate cancer (PCA).
Design, participants and setting:  Observational, prospective study of consecutive 
patients with PCA attending clinics in public hospitals and private practices in 
metropolitan Melbourne between 1 April 2001 and 30 December 2005. Data were 
collected at initial diagnosis of histologically confirmed localised PCA, and close to the 
commencement of definitive treatment (Time 1), and 12 months later (Time 2). Patients 
were stratified according to treatment type (radical prostatectomy [RP], hormone 
therapy [HT] or other early treatment including radiation therapies [OET]). Patients who 
elected to undergo active surveillance/watchful waiting (WW) rather than active 
treatment were treated as a naturalistic control group.
Main outcome measures:  Levels of depression and anxiety were assessed by the Brief 
Symptom Inventory, and physical and psychosocial aspects of health-related quality of 
life (HRQOL) were assessed by the 36-item Short-Form Health Survey.
Results:  211 patients with PCA were recruited; 193 completed the Time 1 
questionnaires (38 RP, 56 HT, 38 OET and 61 WW); and 172 completed the Time 2 
questionnaires (33 RP, 51 HT, 33 OET and 55 WW). At Time 1, the three active treatment 
ps all reported greater dysfunction in work role and daily activities compared with 
W group. The RP group also reported worse social and emotional role functioning, 
 the HT and OET groups reported poorer vitality levels. The HT group reported 
ficantly higher depression scores. At Time 2, the RP and OET groups did not differ 
 the WW group on either HRQOL or psychological status. By contrast, the HT group 
rted significantly worse HRQOL (physical functioning, role-physical and vitality 
ains) and greater psychological distress compared with the WW group.
Conclusions:  Compared with the other active treatments for localised PCA, HT appears 
to be associated with poorer HRQOL and greater psychological distress 12 months after 
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commencing treatment.ro
ma
unP state cancer (PCA) represents ajor health issue in Australia but,like breast cancer in women, little
is known about the psychological impact of
this cancer and its treatments in men.1 PCA
is the most commonly occurring cancer and
second leading cause of cancer death in
Australian men; however, most men survive
for a decade or more following initial diag-
nosis.2 For such men and their doctors,
there is currently a lack of clear guidance
from the scientific literature about which of
the available PCA treatments offers the best
survival/side-effect balance or which clinical
factors in the patient should favour the
choice of one treatment over another.3
The main treatments for localised PCA are:
• Active surveillance/watchful waiting
(WW), which involves no active treatment
• Androgen ablation or “hormone ther-
apy” (HT), which involves oral or injected
drugs to lower circulating androgen levels or
block their action (surgical removal of testes
is now rarely employed); and
• Other early treatments (OET), which
primarily include external beam radiother-
apy (EBRT), where multiple doses of radia-
tion are applied to the prostate gland from
an external source over several weeks, or
brachytherapy, in which low-dose perma-
nent or high-dose temporary radioactive
implants are inserted into the prostate.4
Because each of the active treatment
choices outlined above (RP, HT and OET)
entail troublesome side effects that can have
an enduring impact on physical and psycho-
logical wellbeing, studies that compare
groups of patients who receive different
treatments are needed. There is growing
recognition of the importance of health-
related quality of life (HRQOL) and psycho-
logical wellbeing as pertinent considerations
in addition to patient survival time when
deciding on PCA treatment.5
Here, we use data from our 2001–2005
observational study of patients with local-
ised PCA,6 collected at the time of diagnosis
and initial treatment decision and at 12
months later, to compare psychological sta-
tus (depression and anxiety) and HRQOL as
a function of treatment type at these tem-
poral points.
METHODS
Our multisite study was designed to elicit
data from two cohorts of patients facing PCA:
(i) patients who had just learned they had
localised (potentially curable) PCA; and (ii)
patients who had been told they had meta-
static (incurable) PCA.6 The data reported
here are from the localised PCA cohort.
Patients were consecutive attendees at
participating clinics in public hospitals and
private practices in metropolitan Melbourne
between 1 April 2001 and 30 December
2005, and were recruited into the study by
their oncologists or urologists. Eligible
patients had to have histologically con-
firmed PCA confined to the prostate gland
(ie, no evidence of lymph node involvement
or metastasis). Exclusion criteria included
inability to give informed consent, diagnosis
of another cancer, minimal understanding of
English, psychosis, intellectual disability or
dementia.
Each patient gave written consent to par-
ticipate. Institutional ethics approval was
obtained from human research ethics com-
mittees at each of the seven hospitalsMJA • Volume 190 Number 7 • 6 April 2009
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sity of Melbourne.
Patients completed self-report question-
naires before initiation of definitive PCA
treatment, or as soon as practicable after-
wards (Time 1), and again 12 months later
(Time 2). Demographic data were collected
from all patients. Where geographically
possible, Time 1 questionnaires were
administered in the patient’s home. Care was
taken to ensure that partners and other
family members were not present. After
initial telephone contact to reinforce the
importance of completing the question-
naires independently of family members,
Time 2 questionnaires were sent by mail.
Measures
• The 36-item Short-Form Health Survey
(SF-36)7 is a well validated and reliable self-
report measure both of physical and psycho-
social aspects of HRQOL.8 It has eight sub-
scales — four covering physical health, and
four relating to mental health. There are four
physical health subscales — “physical func-
tion”, “role-physical”, “pain” and “general
health”. “Role-physical” refers to perform-
ance of work or other daily activities with-
out interference from physical impediments.
“Vitality” refers to the balance of energy and
fatigue levels. “Social functioning” is related
to performance of normal social activities
without interference from physical or emo-
tional problems. “Role-emotional” refers to
performance of work or other daily activities
without interference from emotional or psy-
chological impediments. “Mental health” is
related to the balance between feelings of
nervousness and depression and feeling
peaceful, happy and calm. Respondents are
asked to report on their HRQOL over the 4
weeks before the day the questionnaire is
administered. Lower scores on all subscales
indicate poorer functioning.
• The Brief Symptom Inventory (BSI-53)9
is a 53-item self-report measure of psycho-
logical status that has been extensively
used in psycho-oncology research. In addi-
tion to an overall scale for general psycho-
logical distress, it provides nine subscales,
including ones for depression and anxiety
that are reported here. In each case, a
higher score denotes greater psychological
distress. Respondents are asked to report
on their psychological status over the week
before the day the questionnaire is admin-
istered. The BSI-53’s ability to discriminate
clinically distressed from non-distressed
samples has been well established, using
structured psychiatric interviews as bench-
marks. It also has well established reliab-
ility and convergent and predictive
validity.10 It is sensitive to changes in psy-
chological adjustment and to psycho-
pathology in populations of patients with
cancer.11,12
Statistical analysis
In the data presented below, we cite the
number of participants at Time 1 and Time
2 who had complete data. SPSS, version
14.0 (SPSS Inc, Chicago, Ill, USA) was used
throughout. Analyses comprised planned
comparisons between WW and each of the
other three treatments (RP, HT and OET),
based on the assumption that without active
treatment, the men in the WW condition
would form a naturalistic control or com-
parison group over time. Planned compar-
2 Depression, anxiety and health-related quality of life at diagnosis (Time 1) and at 12 months (Time 2) in patients with 
prostate cancer, assessed by scores (mean [SD]) on subscales of the Brief Symptom Inventory and the 36-item Short-Form 
Health Survey
Brief Symptom 

















WW 61 0.147 (0.3) 0.246 (0.4) 85.66 (21.5) 90.98 (25.0) 89.84 (17.0) 72.29 (19.0) 75.08 (15.5) 89.14 (16.0) 87.43 (28.6) 80.59 (16.5)
RP 38 0.289 (0.4) 0.307 (0.6) 79.47 (22.9) 55.26 (45.1)* 84.20 (18.6) 77.16 (15.7) 68.55 (18.6) 75.99 (25.6)† 69.30 (42.0)† 78.53 (17.0)
HT 56 0.348 (0.6)‡ 0.360 (0.5) 79.29 (18.5) 62.95 (40.2)* 83.94 (18.2)§ 66.20 (20.7) 57.60 (21.2)* 81.70 (23.6) 79.17 (35.1) 74.71 (19.5)§
OET 38 0.246 (0.4) 0.237 (0.4) 79.47 (21.4) 68.42 (37.1)* 85.55 (17.9) 64.82 (19.9) 66.45 (19.9)‡ 83.88 (22.5) 77.19 (35.6) 77.89 (15.4)
All 193 0.253 (0.5) 0.289 (0.5) 81.37 (21.0) 71.37 (38.9) 86.17 (17.9) 70.01 (19.5)§ 67.02 (19.8) 83.35 (22.0) 79.45 (35.2) 77.95 (17.3)
Time 2
WW 55 0.169 (0.3) 0.151 (0.2) 83.91 (19.8) 74.09 (39.9) 84.41 (19.8) 71.41 (20.6) 67.09 (19.5) 85.68 (21.8) 80.61 (34.9) 82.54 (14.6)
RP 33 0.252 (0.4) 0.258 (0.4) 86.67 (17.7) 71.97 (36.3) 80.74 (21.3) 74.93 (17.2) 70.15 (17.5) 87.50 (20.0) 87.88 (23.3) 78.67 (14.5)
HT 51 0.355 (0.5)‡ 0.291 (0.4)‡ 66.76 (21.8)* 50.00 (42.1)† 76.64 (21.6)§ 64.06 (22.2)§ 56.18 (18.7)† 81.13 (22.4) 75.82 (36.6) 78.35 (15.4)
OET 33 0.219 (0.4) 0.200 (0.3) 80.76 (19.3) 75.76 (36.2) 82.40 (19.6) 66.76 (21.8) 62.27 (19.7) 86.74 (21.6) 84.85 (30.1) 81.70 (16.3)
All 172 0.250 (0.4) 0.222 (0.3) 78.75 (21.3) 66.86 (40.4) 81.02 (20.7) 69.01 (20.9) 63.51 (19.5) 84.88 (21.6) 81.39 (32.7) 80.39 (15.2)
WW = watchful waiting. RP = radical prostatectomy. HT = hormone therapy. OET = other early treatment, including radiation therapies.
* P < 0.001. † P < 0.01. ‡ P < 0.05. § P < 0.10. Note: statistical significance relates to planned comparisons by means of univariate analysis of variance comparing watchful 
waiting to each of the three active treatment conditions (radical prostatectomy, hormone therapy and other early treatment). ◆
1 Sociodemographic characteristics 
of the sample of 211 participants 
at the time of recruitment
Characteristic Value
Age (years)
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SU PPLEMENTisons were conducted by univariate analysis
of variance (with an alpha level of 0.05).
RESULTS
Referring oncologists and urologists at the
multiple clinical sites identified 211 eligible
patients with localised PCA from clinic
attendees. Their demographic data are
shown in Box 1. Of these 211 patients, 193
completed the Time 1 questionnaires and
172 (89.1% of those at Time 1) completed
the Time 2 questionnaires.
Time 1
At Time 1, the three active treatment groups
all experienced more dysfunction compared
with the WW group (see Box 2); this was
particularly evident in their scores on the
role-physical subscale of the SF-36. In addi-
tion, the men in the RP group reported more
disruption to their social functioning and
emotional role. The HT and OET groups
reported poorer vitality levels. The HT
group had significantly worse depression
scores than the WW group (see Box 2).
Time 2
At Time 2, the HRQOL and psychological
status of the RP and OET groups had
become very similar to those of the WW
group. In contrast, the HRQOL and psycho-
logical status of the HT group appeared to
have deteriorated, with significantly worse
HRQOL with respect to physical function-
ing, physical role and vitality, and greater
psychological distress in comparison to the
WW group (see Box 2). This pattern was
most evident for depression (see Box 2).
DISCUSSION
Our study is unusual in that we: (i) recruited
patients newly diagnosed with PCA who
were receiving all the main types of PCA
treatment; (ii) prospectively measured their
HRQOL and psychological status; and (iii)
compared these outcomes between the
treatment groups after a clinically meaning-
ful period of time had elapsed.
We found that patients in the three active
treatment groups (RP, HT and OET) experi-
enced greater dysfunction initially com-
pared with those in the WW group, but the
HT group alone demonstrated continuing
poor HRQOL with respect to physical func-
tioning, role-physical and vitality 12 months
later. In addition, the HT group alone exper-
ienced an increase in psychological distress
in comparison to the WW group 12 months
after their treatment for PCA started. To our
knowledge, this is the first prospective study
of localised PCA to demonstrate enduring
adverse psychological effects of HT.
Few studies have examined psychosocial
outcome as a function of differential treat-
ment for localised PCA. Some followed
patients prospectively and compared treat-
ments, but did not include all the major
treatments for PCA in their cohort, or did
not collect the data in such a way that each
aspect of treatment could be compared sep-
arately.13-15 For this reason, the adverse
effects over time of HT may not have
become apparent. A Dutch study compared
the psychological impacts of RP and EBRT
in patients with PCA.16 Participants were
recruited before the commencement of
treatment, when they were classified as hav-
ing either high or low pretreatment anxiety.
The authors observed that, within the group
classified as having high pretreatment anxi-
ety, levels of depression (but not anxiety) at
5-year follow-up were greatest in those who
had received EBRT.16 A 2007 United States
study followed a cohort of patients with
localised PCA over 2 years and found no
significant differences between groups
treated with RP, brachytherapy or EBRT in
terms of the mental and physical domains of
the SF-36.17 Although a proportion of
patients in the RP group were reported to
have received adjuvant HT, the authors did
not report an analysis of HT outcomes.17
Only two studies to our knowledge have
examined the specific effect of HT on
HRQOL and psychological status in com-
parison to other treatments. One compared
HRQOL between patients who received RP,
brachytherapy or EBRT at nine US hos-
pitals.18 The researchers documented the
fact that some of the patients who received
the radiotherapies also received adjuvant
HT. Their measure of HRQOL included a
category of “vitality or hormonal function”
which incorporated aspects of depression,
fatigue, weight change, gynaecomastia and
hot flushes. They found that adjuvant HT
was associated with lower vitality and worse
hormonal function outcomes 24 months
after commencement of PCA treatment.18
Another study also examined the contribu-
tion of HT, RP, EBRT and WW to patients’
HRQOL several years after initial PCA treat-
ment.19 This study employed a population-
based cross-sectional design using a cancer
registry that identified all men in the south-
ern part of the Netherlands who were diag-
nosed with PCA over a 4-year period, and
that included information about the PCA
treatment the men received. A comparison
of patients who had received different PCA
treatments more than 6 years earlier showed
that HT was associated with the worst vital-
ity outcome of all the treatment groups, with
RP rating the best, followed by WW and
then EBRT.
Although these two studies suggest
poorer psychological outcomes with HT, it
should be noted that neither used a specific
measure of psychological status equivalent
to the BSI-53 in our study, relying instead on
the mental health components of general
HRQOL measures. Nevertheless, these find-
ings and ours may be pointing to an impor-
tant role for physiological testosterone levels
in maintaining optimal cognitive and emo-
tional functioning of the male human brain.
Alternatively, or in addition, the findings
may point to mens’ psychological response,
over time, to the side effects of medical sex
hormone manipulation — reduced libido,
feminising physical changes (eg, reduced
facial hair growth, loss of muscle bulk,
gynaecomastia and skin changes), and unfa-
miliar and distressing physical symptoms
(eg, hot flushes).4
We believe that the perception that men
generally cope well with the diagnosis of
PCA and its subsequent treatment is chal-
lenged by these emerging findings. A social
expectation of outer masculine fortitude in
the face of a cancer diagnosis, and a possible
reluctance by clinicians to assess thoroughly
their male patients’ psychological status may
be preventing cancer clinicians from gaining
a fuller understanding of the factors that
should be considered when recommending
a particular treatment option to a patient
newly diagnosed with PCA. Furthermore,
such medical attitudes may be preventing
patients from being offered necessary
psychological and psychiatric support once
they commence treatment for PCA.
There are several limitations of our study.
First, recruitment of patients through cancer
clinics introduces a possible selection bias,
as not all men with PCA in the community
had an equal chance of being recruited.
Although the use of cancer registries reduces
selection bias, inevitable delays between
diagnosis and inclusion in the register pre-
clude access during the critical period when
patients are grappling with the implications
of a cancer diagnosis. Accurate and reliable
assessment of psychological adjustment to
PCA clearly requires measuring psycho-
social variables in real time. Recruitment
through advertisements or from information
sessions and self-help groups is prone toS88 MJA • Volume 190 Number 7 • 6 April 2009
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select. For these reasons, using consecutive
clinic attendees is common in psycho-
oncology research.
A second limitation is attrition, but a
substantial proportion of patients — nearly
90% — participated in the follow-up.
Finally, we recruited English-speaking men
only, so there are limits to how far we can
generalise our results to non-English-speak-
ing groups in the community.
We acknowledge that multiple factors
(such as age, marital status, previous medi-
cal history) could influence the treatment
the doctor recommends, whether the
patient accepts the recommendation, and
the ultimate psychological outcome for the
patient. This is an important area for future
research.
In summary, our findings suggest that
psychological distress was greater with HT
than with RP and OET, neither of which had
distress levels significantly different from
that with WW 12 months after PCA treat-
ment commenced. Perhaps HT is less well
tolerated by patients, but further research is
needed to ascertain the reasons for our
observation. Future studies should examine
separately the psychosocial impact of HT,
and explore whether there are mediating
factors. The implications for counselling,
psychological and psychiatric support are
clear — clinicians should be particularly
diligent in monitoring men receiving HT so
that any adverse psychological effects may
be promptly identified and treated.
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